Anemia is a decrease in circulating red blood cells that contributes to a complex group of symptoms. Anemia may be present in more than half of all patients with cancer but often is assessed, documented, prevented, and treated inadequately. Individuals with cancer are living longer, and the number of cancer treatment options provided at various points in the cancer continuum is growing; however, many treatments contribute to anemia. Because anemia can develop from multiple causes, treatment must be tailored to the underlying etiology. Cancer-related anemia can signifi cantly affect therapeutic outcomes and patients' quality of life. Therapeutic interventions may include blood transfusions, administration of recombinant human erythropoietin, and interventions to support patient symptoms, most signifi cantly, fatigue. Oncology nurses play a central role in risk assessment, symptom management, treatment planning, and evaluation and therefore must understand the etiology and physiology of cancer-related anemic states as well as evidence-based interventions to ensure optimal outcomes.
I
n patients with cancer, anemia can result from secondary blood loss, displacement of normal bone marrow cells by malignant cells, myelotoxic therapy, or a tumor, yet the condition may not become evident unless it represents a source of signifi cant symptoms or patient distress. Risk factors for anemia development include platinum-based treatment regimens, specifi c tumor types, and low baseline hemoglobin levels. Anemia has the potential to impact patient performance status, quality of life, clinical symptoms, therapeutic effi cacy, and survival. Treatment interventions directed toward the underlying etiology of anemia involve iron supplementation, blood transfusion, and administration of recombinant human erythropoietin (rHuEPO). Novel approaches that may add to the complement of strategies designed to address anemia in patients with cancer are being developed (Cella, Dobrez, & Glaspy, 2003; Gillespie, 2003; Groopman & Itri, 1999; Mercadante, Gebbia, Marrazzo, & Filosto, 2000) .
Although considerable progress has been made in preventing or alleviating many of the common toxicities associated with cancer and its therapy, anemia continues to be frequently overlooked and undertreated (Loney & Chernecky, 2000) . Anemia contributes to fatigue, a symptom that adversely affects functional status and causes considerable distress to patients and their families (Stovall & Young, 2006; Von Gunten, 1999) . In addition, the lack of a standard defi nition regarding symptomatic anemia requiring intervention and the availability of suboptimal assessment tools further complicate the problem of anemia in patients with cancer (Gillespie, 2003; Groopman & Itri, 1999) . Oncology nurses are pivotal to the care of patients with cancer-related anemia (CRA) because they are a constant presence along the continuum of care; therefore, oncology nurses must be able to identify pertinent assessment criteria, identify patients at risk, carry out evidence-based interventions, and evaluate therapeutic outcomes.
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Causes of Cancer-Related Anemia
Anemia is defi ned as a decrease in the volume of circulating red blood cells (RBCs) or the concentration of hemoglobin resulting in the body's diminished ability to carry oxygen to tissues (Lynch, 2006d) . The causes of anemia may be multifactorial, especially in patients with cancer undergoing multiple and prolonged treatment regimens. Anemia may result from decreased RBC production, increased RBC destruction, decreased circulating RBCs, or a combination of those factors, as well as other compounding reasons (e.g., poor dietary intake of iron), which often is the case in patients with cancer (Loney & Chernecky, 2000) . Inadequate production of RBCs may result from defects in erythropoietin-producing cells, DNA synthesis, hemoglobin synthesis, bone marrow suppression, or renal failure (Lynch, 2006d) . RBC destruction is caused by many factors such as intrinsic factors (e.g., enzyme defi ciencies) or cancer-related extrinsic destruction by chemotherapeutic agents (e.g., antimetabolites), the malignancy itself stimulating an autoimmune hemolysis (e.g., chronic lymphocytic leukemia), or infl ammatory cytokines produced by the malignancy destroying RBCs (e.g., tumor necrosis factor) (Loney & Chernecky; Lynch, 2006d; Worrall, Tompkins, & Rust, 1999) . Decreased circulating RBCs can result from acute hemorrhage or cancer-related coagulopathies as in disseminated intravascular coagulation. In patients with cancer, compounding factors such as defi ciencies in iron, vitamin B 12 , and folate present risks for decreased production and loss of circulating RBCs (Loney & Chernecky) .
The etiology of anemia often is classifi ed according to the size of the RBC, which is determined by evaluation of the mean corpuscular volume laboratory data. Anemia may be classifi ed as microcytic, normocytic, and macrocytic (Lynch, 2006d ) (see Table 1 ). Other classifi cations may be based on RBC morphology, including the amount of pigment, noted by the mean corpuscular hemoglobin (e.g., hypochromic, normochromic), or by the reticulocyte count, which delineates the productive capacity of the bone marrow to meet the RBC requirements of the body. A low reticulocyte count demonstrates decreased RBC production, whereas a high reticulocyte count indicates increased RBC destruction (Lynch, 2006d) .
Microcytic Anemia
Two common causes of microcytic anemia in patients with cancer are iron defi ciency or comorbid chronic disease states. In microcytic anemia, the RBC is small in size (i.e., mean corpuscular volume < 80 fl ). In patients with iron defi ciency, microcytic anemia is caused by insuffi cient iron for hemoglobin synthesis. Iron defi ciency anemia is the most common cause of anemia worldwide, occurring frequently in young children, pregnant women, and older adults (Lynch, 2006c; Worrall et al., 1999) . In patients with cancer, the most frequent causes of iron defi ciency are inadequate absorption (e.g., gastrectomy), excessive loss of iron because of blood loss (i.e., uterine, gastrointestinal, or genitourinary tract bleeding) (Lynch, 2006c) , or other cancerrelated effects such as anorexia resulting in poor dietary intake of iron (Loney & Chernecky, 2000) . Differential diagnoses for iron defi ciency microcytic anemia in patients with cancer include other hematologic disorders such as thalassemia minor and sideroblastic anemia (Lynch, 2006c) .
Malignancies and other conditions such as chronic infection, infl ammatory conditions, and congestive heart failure contribute to a common set of factors resulting in anemia and are referred to as anemia of chronic disease (ACD). ACD is triggered by immune and infl ammatory cytokines that are common to those conditions, specifi cally tumor necrosis factor, interleukin-1, and interferon (Cella et al., 2003) . Reduced erythropoietin production results from inhibition of RBC precursors in the bone marrow, impaired iron uptake by developing RBCs, or erythropoietin inadequately released from the kidneys (Lynch, 2006a) . Chronic infections decrease the stem cell pool in addition to reducing the body's response to erythropoietin stimulation (Loney & Chernecky, 2000) .
The reticulocyte count is the productive capacity of the bone marrow to meet the RBC requirements of the body. Patients with ACD have a low reticulocyte count, indicating a hypoproliferative state. Differential diagnoses for microcytic ACD in patients with cancer include other hematologic disorders such as aplastic anemia, bone marrow suppression caused by myelodysplasia or chemotherapy, and anemia resulting from chronic renal failure (Lynch, 2006a) .
Normocytic Anemia
In its early stages, ACD may present as normocytic anemia, a state in which RBCs are normal in size. Classifi cation by RBC (Smith & Tchekmedyian, 2002) . Severe catabolism associated with cancer also may impair protein production, rendering the bone marrow unable to effectively produce an adequate number of RBCs (Smith & Tchekmedyian) yet those present remain normal in size. The processes of erythropoietin production and erythropoiesis are essential in stimulating the bone marrow for RBC production and maturation. A normal feedback loop occurs when hypoxia in the renal cells triggers release of erythropoietin from the bone marrow (Loney & Chernecky, 2000) . As a result, decreased RBC production can be caused by kidney damage related to a tumor or nephrotoxic chemotherapy or, rarely, radiation renal injury, as well as other coexisting causes of renal insuffi ciency such as end-stage renal disease (Worrall et al., 1999) .
Other causes of hemolytic anemia in patients with cancer may include autoimmune hemolysis (e.g., cold agglutinin antibodies), enzyme defi ciencies (e.g., glucose-6-phosphate genase), or RBC destruction by tumor (e.g., non-Hodgkin lymphoma), chemotherapeutic agents (e.g., cisplatin), total body irradiation (e.g., bone marrow transplant), or risks associated with cancer and its treatment (e.g., disseminated intravascular coagulation). In addition, nonchemotherapeutic medications common to cancer protocols can contribute to anemia (e.g., lorazepam) (Loney & Chernecky, 2000; Lynch, 2006d; Worrall et al., 1999) .
Macrocytic Anemia
Abnormal maturation of RBCs contributes to macrocytic or large cells (> 100 fl ), such as in vitamin B 12 and folic acid deficiencies which interfere with DNA synthesis necessary for RBC precursors (Worrall et al., 1999) . Impaired absorption of vitamin B 12 (cobalamin) may be related to defi ciency of intrinsic factor secreted by the parietal cells of the stomach (e.g., total gastrectomy). Pernicious anemia is an autoimmune reaction that causes atrophy of the gastric mucosa and failure of intrinsic factor secretion (Lynch, 2006b; Worrall et al.) (see Figure 1 ). Vitamin B 12 or intrinsic factor defi ciency causes megaloblastic, macrocytic, normochromic anemia and occurs more commonly in the sixth decade of life. It is insidious in nature because of bodily stores of vitamin B 12 , yet defi ciencies may occur in patients who are strict vegetarians (e.g., no dairy or meat), in those with bacterial infections of the gastrointestinal tract, or when precipitated by certain medications (e.g., cimetidine) (Lynch, 2006b; Worrall et al.) . Vitamin B 12 is necessary for the metabolism of folate. Bodily stores of folate are not abundant; therefore, dietary intake (e.g., green leafy vegetables) is important. Defi ciencies in folic acid may occur because of alcoholism, liver disease, malabsorption syndromes, and anorexia. In patients with cancer, medications may lead to folic acid defi ciencies such as anticonvulsants (e.g., phenytoin) and folic acid antagonists (e.g., hydroxurea, methotrexate, pemetrexed) (Worrall et al.) . Differential diagnoses for macrocytic anemia include vitamin B 12 or intrinsic factor deficiency, folate defi ciency, ACD, and myelodysplastic syndromes (Lynch, 2006b) .
The causes and risks for CRA include iron, vitamin B 12 , and folate defi ciencies; the malignancy itself; treatment; infl ammation; infection; comorbid disease (e.g., renal failure); and hemolysis (Worrall et al., 1999) . The causes of CRA are multiple and complex and therefore require astute clinical evaluation to determine patient risk factors and the underlying etiology. A clinical guide for delineating the causes of anemia can be found in Figure 2 .
Impact of Cancer-Related Anemia
Despite the diffi culties in assessing anemia and its related symptoms, trends in the prevalence of anemia in patients with cancer have been identifi ed. Some tumor types reportedly correlate with high rates of anemia, such as lung cancer (52%) and ovarian cancer (51%). The high incidence probably is related to the advanced age of many patients with lung cancer and the frequent use of platinum-based therapies for tumors at both sites (Gillespie, 2002) . The options for multiple chemotherapy protocols are increasing and individuals with cancer are living longer after treatment; therefore, the effect of anemia on patients' quality of life and their response to treatment will continue to present challenges for healthcare professionals (Hudis, Van Belle, Chang, & Muenstedt, 2004) .
Physical and Psychosocial Impact
The physical and psychosocial impact of undetected CRA can be profound (Loney & Chernecky, 2000) . A major complication of anemia is fatigue. Anemia results in decreased oxygen delivery to tissues and, when untreated, eventually leads to a negative energy balance (Gutstein, 2001) . According to patient
Figure 1. Photomicrograph of Pernicious Anemia in Bone Marrow Cells
Note. Copyright C. James Webb/Phototake. All rights reserved. Reprinted with permission. RBC-red blood cell reports, fatigue is the most distressing symptom associated with cancer and its treatment (Mock, 2001) . As cancer treatment protocols have become more dose dense and dose intensive, the risk of anemia has increased, as well as the likelihood that cancer-related fatigue will become more distressing for patients, adversely affecting their quality of life (Mock) . Fatigue is diffi cult to assess objectively because it is a multifactorial and multidimensional symptom with physical, emotional, and cognitive effects (Escalante et al., 2001; Von Gunten, 1999) . Fatigue has been defi ned as "a subjective state of overwhelming sustained exhaustion and decreased capacity for physical and mental work that is unrelieved by rest" (Escalante et al., p. 1708) . The signifi cant loss of energy associated with even mild anemic states can limit patients' ability to perform everyday activities, including work, social, and leisure activities. Fatigue also has been correlated with loss of self-esteem, anxiety, depression, and emotional stress (Escalante et al.) . Severe fatigue may diminish patients' ability to cope with cancer and its treatment. In a literature review, Von Gunten reported that correcting anemiarelated fatigue correlated with at least a modest improvement in overall quality of life and energy levels.
Other disturbing symptoms that occur with anemia are caused by increased cardiac output, shunting of blood to vital organs, and peripheral vascular dilation (Cella et al., 2003; Hudis et al., 2004) . Mild anemia can cause tachycardia, palpitations, and dyspnea on exertion (Loney & Chernecky, 2000) . Severe anemia results in disabling fatigue states, compounds tachycardia and dyspnea, and may precipitate headaches, dizziness, mood changes, and diffi culty concentrating, whereas prolonged anemia may cause insomnia, anorexia, indigestion, menstrual irregularities, and sexual dysfunction (Loney & Chernecky).
Anemia's Impact on Treatment and Survival
Hypoxia, a characteristic feature of locally advanced solid tumors, has been recognized as a critical factor in promoting tumor resistance to radiotherapy, chemoradiation, and some chemotherapeutic agents (Littlewood, 2001; Shasha, 2001) . In a systematic review to determine whether anemia was an independent prognostic factor for cancer survival, the overall risk of death increased by 65%, adjusting for variables, in anemic patients with cancer relative to those without anemia (Caro, Salas, Ward, & Goss, 2001 ).
Severe anemia may have an impact on therapies used to manage cancer. Anemia may delay surgical interventions when treatment requires preoperative correction through RBC transfusion. Similarly, low levels of hemoglobin before or during chemotherapy cycles may require dose reductions or delays in administration, resulting in a decrease in the overall treatment intensity. Tumor hypoxia also may limit the effectiveness of oxygen-dependent chemotherapy (Cella et al., 2003; Kelleher, Mattheinsen, Thews, & Vaupel, 1996) .
Hemoglobin levels are reported to be a strong independent prognostic factor for tumor control by radiation therapy, with the hemoglobin level at the conclusion of therapy believed to be more important than the baseline level (Finney & Allison, 2005; Lavey, 1998) . Cells that are not fully oxygenated are substantially less sensitive to the effects of ionizing radiation. The proportion of cells killed by a given dose of radiation under well-oxygenated conditions is termed oxygen enhancement ratio. Radiation biologists have hypothesized that minimally oxygenated tumor cells most distant from the capillary are relatively resistant to radiotherapy and are the most likely source of local treatment failure. In addition, anemia may increase local failure rates by exacerbating local tumor hypoxia (Caro et al., 2001; Harrison, Shasha, White, & Ramdeen, 2000) . Although the link among treatment of preexisting mild anemia, local control, and cure rates for radiation therapy has not been suffi ciently confi rmed in randomized clinical trials, most clinicians accept the premise that anemia compromises radiotherapy and that it merits careful attention when cure or improved survival is a potential therapeutic outcome (Finney & Allison; Glaspy, 2002) . Hemoglobin levels have been strongly correlated with tumor size, which may explain the poorer outcomes reported for patients with anemia receiving radiation therapy in earlier published studies (Gillespie, 2003) .
Assessment Criteria
Assessment begins with a thorough history that identifi es patients who are at risk for developing anemia or symptoms that may be changing over time such as fatigue-related lifestyle changes (Loney & Chernecky, 2000 ) (see Figure 3) . Physical examination must include all organ systems and may reveal pallor, tachycardia, systolic ejection murmur (S3 extra heart sound), shortness of breath on activity, and pedal edema (Loney & Chernecky) . Careful assessment of anemia and its related symptoms is made more diffi cult by the lack of a standard defi nition of the condition, the absence of gender-specifi c differences in normal hemoglobin levels, and variable trigger points leading to transfusion (Gillespie, 2003) . Individual assessments should evaluate current blood counts and other pertinent laboratory values (see Figure 4 ). Physical symptoms (e.g., pulmonary, cardiac) should be ascertained as well as changes in trends related to the fi ndings over time. Patients who become more symptomatic, as compared with baseline values, may be experiencing an increase in the severity of anemia, even if the hemoglobin level has not decreased to very low levels.
Complicating the assessment, objective fi ndings in symptomatic patients with a given hemoglobin value cannot be generalized to others with similar values (Gillespie, 2003) . Laboratory data play a pertinent role in the assessment of anemia, and nurses should be familiar with normal ranges for the complete blood count with indexes (see Table 2 ). When indicated, standards of practice recommend that anemia assessment should include examination of the peripheral smear, bone marrow aspiration and biopsy (e.g., hypocellular marrow found in aplastic anemia), and serum creatinine to evaluate renal function (Earles, 2004; Lynch, 2006c) .
Astute patient assessment is vital to differentiate anemia-related symptoms such as fatigue and mood changes from other major diagnoses (e.g., depression, chemotherapy-induced cognitive changes). The underlying cause of anemia must be determined for the optimal intervention to be designed. Concomitant processes, such as nutritional defi ciencies, infl ammation, infection, hemolysis, blood loss, and other diagnoses in the context of cancer, should be evaluated as well as information about the impact of current or previous myelosuppressive therapy (Groopman & Itri, 1999) . Multiple causes of anemia exist, and treatment is tailored to the cause. The degree of anemia is not always refl ective of the severity of the causative disorder; therefore, careful and thorough assessment, including attention to patterns that patients experience, is critical in anemia treatment (Gillespie, 2003; Groopman & Itri; Tavio, Milan, & Tirelli, 2002) . Quantitative assessment scales such as the Anemia Subscale of the Functional Assessment of Cancer Therapy and the Brief Fatigue Inventory can be used to assess the impact of fatigue on patients' daily activities. Nurses also can incorporate a 0-10 numeric rating scale or a descriptive scale (e.g., mild, medium, severe) into their patient assessments (Earles, 2004 ).
Symptom Management
Correction or management of the underlying etiology in patients with documented anemia is the optimal outcome (Gillespie, 2003; Tavio et al., 2002) . Once the source of anemia has been determined, treatment can be initiated. Supportive interventions include transfusion therapy, erythropoiesis-stimulating therapies, iron supplementation, nutrition, and patient education (see Figure 5 ). Because multiple causes of anemia may be present in an individual, more than one therapy often is necessary.
Evidence-based guidelines for the treatment of anemia in patients with cancer have been established (Earles, 2004) . Joint practice guidelines were adopted by the American Society of Clinical Oncology and the American Society of Hematology in 2002 (Rizzo et al., 2002) , and the National Comprehensive Cancer Network (NCCN) published an updated version of guidelines in 2007. The standards of care for CRA must be incorporated into clinical practice to ensure consistency and benefi t for patients (Berger, 2005) .
Transfusion Therapy
The NCCN (2007) guidelines defi ned levels of hemoglobin to guide interventions-mild anemia (10-11 g/dl), moderate anemia (8-10 g/dl), and severe anemia (< 8 g/dl). When clinical symptoms warrant immediate correction, transfusion therapy is appropriate (Earles, 2004) . Packed RBCs usually are administered for a hemoglobin level less than 8 g/dl, raising the level of hemoglobin quickly to ensure adequate oxygencarrying capacity to vital organs and improving overall clinical status (Von Gunten, 1999) . Symptoms of anemia generally are relieved and quality-of-life data support that optimal improvement occurs when the hemoglobin level ranges from 11-12 g/dl (Earles) . Although the blood supply in the United States is considered extremely safe, RBC transfusion is not without accompanying risk and patients often are concerned about the hazards (Gillespie, 2002 (Gillespie, , 2003 . The potential for transfusion reactions (e.g., allergic, febrile, hemolytic), as well as other possible risks (e.g., alloimmunization, immunosuppression, iron or circulatory overload, transfusion-related acute lung injury, transfusion-transmitted infectious agents), should be considered prior to initiation of transfusion therapy (Gillespie, 2002 (Gillespie, , 2003 Perrotta & Snyder, 2001) . Some patients may have religious beliefs prohibiting the use of blood or blood products (Gillespie, 2003) .
Not only does transfusion therapy rapidly correct anemia and related symptoms, it reduces delays in cancer treatment because of anemia. However, quantifi able disadvantages must be considered, including supply issues, expenses associated with blood products and their administration, and the inconvenience for patients undergoing several hours of administration. The risks and benefi ts of transfusion therapy must be weighed carefully in each situation (Buchsel, Murphy, & Newton, 2002; Groopman & Itri, 1999 ) and transfusion of RBCs should be initiated only if anemia is so severe that inadequate time exists to permit the use of an erythropoiesis-stimulating therapy (Gillespie, 2003) or in cases of anemia that are not responsive to iron, vitamin B 12 , folate, or dietary supplementation.
Erythropoiesis-Stimulating Therapies
Erythropoietin is a naturally occurring hormone produced by the kidneys to regulate RBC production and specifi cally acts at the colony-forming unit-erythroid of the bone marrow to promote erythroid stem cell development into mature circulating erythrocytes (Buchsel et al., 2002) . The production of erythropoietin is regulated by a feedback loop in which the kidney senses decreased oxygen or tissue hypoxia, decreased arterial oxygen, anemia, or increased hemoglobin affi nity and releases erythropoietin (Buchsel et al.; Groopman & Itri, 1999; Tong & Nissenson, 2001) .
With advances in recombinant DNA technology and the ability to manufacture hematopoietic growth factors, the introduction of rHuEPO (epoetin alfa) in the 1990s represented a signifi cantly new approach to treatment and potential reduction in CRA and other conditions, such as chronic renal failure, zidovudine-treated patients with HIV, and patients with anemia undergoing elective, noncardiac, nonvascular surgery (Buchsel et al., 2002 ). Epoetin's mechanism of action and its immunologic and hematologic properties are equivalent to those of endogenous erythropoietin (Amgen Inc., 2006b; Faulds & Sorkin, 1989) .
In patients whose endogenous erythropoietin levels are abnormally low considering the degree of anemia experienced, the administration of exogenous erythropoietin may be benefi cial. Conversely, if endogenous levels of erythropoietin are adequate, the addition of exogenously administered erythropoietin may be of little help in alleviating the anemia (Gillespie, 2003) . For example, in patients with myelodysplasia, erythropoietin levels less than 200 mu/ml are predictive of insensitivity to epoetin (Earles, 2004) . Other causes of low response include vitamin defi ciencies, decreased iron stores, or infectious processes (Buchsel et al., 2002) .
Prior to starting any patient on an erythropoietin-stimulating therapy, NCCN (2007) has recommended a thorough evaluation of CRA to rule out nutritional defi ciencies of vitamin B 12 , iron, and folate, in addition to assessing for hemolysis (e.g., hemoglobin electropheresis) and evidence of gastrointestinal bleeding (e.g., guaic testing). Other pertinent laboratory testing must be carried out to identify a noncancer-or nontreatment-related cause of anemia because the underlying cause must become the initial focus of treatment (e.g., normocytic anemia caused by hypothyroidism).
Epoetin alfa: Epoetin alfa (Procrit , Ortho Biotech Products, LP; Epogen , Amgen Inc.) was approved by the U.S. Food and Drug Administration (FDA) in 1993 for the treatment of anemia in patients with nonmyeloid malignancies (Earles, 2004) . Epoetin alfa stimulates the division and differentiation of erythrocyte stem cells in the bone marrow, resulting in the release of reticulocytes into the blood stream in 7-10 days where they mature into erythrocytes. The process of increasing the hemoglobin takes two to six weeks (Wilkes & Barton-Burke, 2005) .
NCCN (2007) recommended beginning treatment with epoetin alfa using either 150 U/kg subcutaneously three times weekly or 40,000 units weekly. Doses are titrated up to 300 units/kg three times weekly or 60,000 units every week if the hemoglobin has not risen by at least 1-2 g/dl after four weeks (Amgen Inc., 2006b; Ortho Biotech Products, LP, 2006) . Doses are reduced by 25% if the hemoglobin increases by more than 1 g/dl in a two-week period, and therapy is held if hemoglobin exceeds 12 g/dl (NCCN).
Erythropoietin has been shown to raise the mean hematocrit in patients with chemotherapy and CRA, independent of tumor type or disease response, signifi cantly improving energy levels and quality of life (Demetri, Kris, Wade, Degos, & Cella, 1998; Gabrilove et al., 2001; Glaspy et al., 1997) . NCCN (2007) guidelines also recommended that prophylactic rHuEPO be administered in asymptomatic patients with known risk factors (e.g., history of blood transfusions) or in any symptomatic patients (e.g., fatigue). Administration of epoetin alfa early in cancer therapies with known myelosuppressive risk may prevent adverse effects on clinical outcomes, but continued research is needed to identify the role of prophylactic use of erythropoietin therapy across different tumor types and treatment modalities (Earles, 2004; Gillespie, 2003; Mercadante et al., 2000) .
Darbepoetin alfa: A novel erythropoiesis-stimulating agent for CRA is darbepoetin alfa (Aranesp , Amgen Inc.). Darbepoetin alfa has a mechanism of action similar to rHuEPO, but it is biochemically distinct with a half-life two to three times longer than that of rHuEPO, as demonstrated in patients with chronic renal failure (Gillespie, 2003; Vanrenterghem, Barany, & Mann, 1999) . The agent has demonstrated equivalent effi cacy in maintaining hemoglobin levels when administered as a single weekly injection instead of the two to three weekly injections required for rHuEPO (Macdougall, 2000) . Darbepoetin alfa given every two weeks also has been shown to be as effective as weekly dosing of the drug (Vanrenterghem et al.) .
The FDA approved darbepoetin alfa in 2002 for chemotherapy-induced anemia in patients with nonmyeloid malignancies (Gillespie, 2003) . Current NCCN (2007) recommendations include initiating therapy at 2.25 mcg/kg every week or a fi xed dose of 500 mcg every three weeks. Alternative fi xed dosing of 100 mcg every week, 200 mcg every two weeks, or 300 mcg every three weeks are noted as well with suggested titrations for poor response (Amgen Inc., 2006a; NCCN) .
The dose of 200 mcg every two weeks has been compared to epoetin alfa 40,000 units every week. At those doses, darbepoetin alfa and epoetin alfa appeared to have similar effectiveness in terms of hematopoietic response and decrease the need for blood transfusions (Herrington et al., 2005) . Less frequent dosing of darbepoetin alfa has cost-effective and quality-of-life advantages. Administration every three to four weeks reduces drug costs as well as the nursing time needed to prepare, administer, and monitor the medication's effects. The long half-life of darbepoetin alfa may allow the medication to be synchronized with chemotherapy cycles, reduce patient offi ce visits, enhance patient compliance (Demetri, 2001; Earles, 2004; Gillespie, 2003) , and decrease patient and caregiver burden (Koopman & Iakiri, 2005; Longfi eld, Gebhart, & Hayward, 2005) .
Risks Associated With ErythropoiesisStimulating Therapies
The companies producing erythropoietin (Ortho Biotech Products, LP, and Amgen Inc.) and darbepoetin alfa (Amgen Inc.) released revised prescribing information in December 2005 based on the FDA (2005) MedWatch Safety Program. Two recommendations directly affect nursing assessment and monitoring of patient response to erythropoiesis-stimulating therapies.
First, the revised package inserts recommended dosing interruption and/or modifi cation based on hemoglobin levels for patients receiving growth factor support related to cancer chemotherapy. Hemoglobin levels should not exceed 12 g/dl for either therapy. The recommendations resulted from investigational studies conducted outside of the United States, where patients with cancer were treated to high hemoglobin target levels, beyond the correction of anemia. The studies permitted or required dosing with either erythropoiesis-stimulating therapy to achieve hemoglobin levels more than 12 g/dl. An increased frequency of adverse patient outcomes, including increased mortality and thrombotic vascular events, was reported in the studies (Amgen Inc., 2006b; Ortho Biotech Products, LP, 2006) . Second, the FDA warned that, although rare, the presence of neutralizing antibodies to erythropoietin have caused serious adverse reactions, including pure red cell aplasia and severe anemia compounded by other cytopenias (Amgen Inc., 2005) . Patients with chronic renal failure are most susceptible to the reactions; however, oncology nurses must be aware of the risks and monitor for signs and symptoms indicative of increasing anemia (e.g., increasing fatigue, pallor). Because of the rapid proliferation of stem cells with the therapies, oncology nurses should be aware of other possible adverse reactions. Both medications are contraindicated in patients with uncontrolled hypertension or any patient with a known hypersensitivity to substances in the product (e.g., mammalian cell-derived products, human albumin) (Buchsel et al., 2002; Gillespie, 2003) . Finally, additional adverse reactions seen in patients treated with darbepoetin alfa have included pulmonary embolism, deep vein thrombosis, and edema (Amgen Inc., 2006a; Gillespie, 2003) .
Iron supplementation: Iron supplementation may be required in combination with erythropoiesis-stimulating therapies to treat anemia effectively (NCCN, 2007) , and supplementation also may reduce the total amount of rHuEPO needed to correct hemoglobin levels. The transport of iron is necessary for the process of erythropoiesis. Inadequate use and transport of iron, termed functional iron defi ciency, are the most common causes of an inadequate response to rHuEPO among patients with chronic renal failure (Feelders et al., 1998; Gillespie, 2002) , and functional iron defi ciency also may be an important factor in chronic anemia in cancer. NCCN, the American Society of Clinical Oncology, and the American Society of Hematology guidelines advised that iron studies be carried out periodically for all patients receiving erythropoietic therapy (Rizzo et al., 2002) , and Medicare guidelines require that all patients receiving chemotherapy have iron studies carried out prior to treatment initiation (Gaits, Shaftic, & Terlizzi, 2005; Miskin & Hoechner, 2005) . Iron supplementation may be given orally or via IV, although signifi cant gastrointestinal discomfort and potential noncompliance can result from oral administration (Glaspy & Cavill, 1999) . IV iron supplementation, however, can be inconvenient and costly and is associated with signifi cant adverse events such as anaphylaxis. Standardization of laboratory monitoring and documentation of iron and folate supplementation, as well as patient outcomes, continue to be challenges in clinical settings (Gaits et al.) .
Patient Education
Educating patients with CRA complements adjuvant therapy and is a necessary component of a comprehensive protocol. Education will promote patient compliance, give patients a sense of control, and improve treatment outcomes. Prior to the initiation of cancer treatment, patients should be instructed about possible side effects, including anemia and its related symptoms, especially fatigue. Providing patients with the appropriate knowledge to understand diagnosis and treatment enables them to become active partners in the plan of care and equips them to recognize any physical or lifestyle changes over time and notify the healthcare team for immediate intervention. Fatigue is the cardinal symptom of anemia (Gillespie, 2002) , and oncology nurses play a pivotal role in educating patients about selfcare skills to minimize the negative effects of fatigue on daily activities and quality of life (Mock, 2001; Ream & Richardson, 1999; Stovall & Young, 2006) . Fatigue management includes identifying personal limitations, conserving energy, planning ahead for the effi cient use of energy, alternating rest and activity periods, keeping regular sleep schedules, and exercising safely within capabilities (Portenoy & Itri, 1999) . Education regarding nutrition is important to combat fatigue and vitamin defi ciencies. If iron supplementation is required, patients should be advised regarding appropriate medication requirements (e.g., bowel regimen to prevent constipation). Integrating stress management techniques and cognitive therapies can minimize the impact of symptoms related to fatigue (Portenoy & Itri) . Personal treatment diaries can provide subjective assessments on activity levels and actual nutrition and hydration intake, in addition to giving patients a sense of control and the means to identify changes over time.
Conclusion
Oncology nurses play a central role in risk assessment, symptom evaluation, evidence-based interventions, and determination of treatment options for their patients with CRA, making a signifi cant contribution to improving patients' quality of life and positively infl uencing clinical outcomes. Anemia traditionally has been a symptom that rarely was assessed carefully, perceived as producing little or no change in cancer outcomes (Gillespie, 2003) . With the advent of erythropoiesis-stimulating therapies and the recognition of the debilitating impact of fatigue, the symptom clusters caused by CRA can no longer be ignored. Implementation of standards of care, essential laboratory studies, necessary iron and folate supplementation, pertinent documentation, and clinical monitoring of patient status have been widely inconsistent (Berger, 2005) . Oncology nurses are in a key position to rectify clinical discrepancies and contribute to the research that is needed to determine the most effective interventions for patients (Berger) . The impact of erythropoietic therapy on treatment response and survival outcomes and the role of prophylactic treatment with these agents still must be determined. Clinical management of anemia requires a comprehensive and holistic approach (Loney & Chernecky, 2000) across all patient care settings-goals inherent in the role of oncology nurses.
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